- Home
- OCS vs QURE Comparison
OCS vs QURE Comparison
Compare OCS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- QURE
- Stock Information
- Founded
- OCS 2003
- QURE 1998
- Country
- OCS Switzerland
- QURE Netherlands
- Employees
- OCS N/A
- QURE N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- QURE Health Care
- Exchange
- OCS Nasdaq
- QURE Nasdaq
- Market Cap
- OCS 869.8M
- QURE 866.3M
- IPO Year
- OCS N/A
- QURE 2007
- Fundamental
- Price
- OCS $21.71
- QURE $64.18
- Analyst Decision
- OCS Strong Buy
- QURE Strong Buy
- Analyst Count
- OCS 4
- QURE 12
- Target Price
- OCS $41.00
- QURE $69.67
- AVG Volume (30 Days)
- OCS 77.9K
- QURE 7.7M
- Earning Date
- OCS 11-06-2025
- QURE 11-04-2025
- Dividend Yield
- OCS N/A
- QURE N/A
- EPS Growth
- OCS N/A
- QURE N/A
- EPS
- OCS N/A
- QURE N/A
- Revenue
- OCS $960,668.00
- QURE $14,337,000.00
- Revenue This Year
- OCS $36.75
- QURE N/A
- Revenue Next Year
- OCS $1,261.53
- QURE $287.72
- P/E Ratio
- OCS N/A
- QURE N/A
- Revenue Growth
- OCS N/A
- QURE N/A
- 52 Week Low
- OCS $14.00
- QURE $5.35
- 52 Week High
- OCS $23.08
- QURE $65.14
- Technical
- Relative Strength Index (RSI)
- OCS 76.98
- QURE 70.59
- Support Level
- OCS $21.19
- QURE $57.64
- Resistance Level
- OCS $21.79
- QURE $65.14
- Average True Range (ATR)
- OCS 0.66
- QURE 4.32
- MACD
- OCS 0.28
- QURE -0.74
- Stochastic Oscillator
- OCS 93.88
- QURE 93.31
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.